{"id":390173,"date":"2020-08-25T00:00:00","date_gmt":"2020-08-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0006-2020-biopharma-multiple-sclerosis-current-treatment-physician-insights-u-s-2020\/"},"modified":"2026-03-31T10:44:41","modified_gmt":"2026-03-31T10:44:41","slug":"cutrcg0006-2020-biopharma-multiple-sclerosis-current-treatment-physician-insights-u-s-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0006-2020-biopharma-multiple-sclerosis-current-treatment-physician-insights-u-s-2020\/","title":{"rendered":"Multiple Sclerosis | Current Treatment: Physician Insights | U.S. | 2020"},"content":{"rendered":"<p>Three disease-modifying therapies (DMTs)\u2014EMD Serono\u2019s Mavenclad, Novartis\u2019s Mayzent, and Biogen\u2019s Vumerity\u2014joined the crowded U.S. multiple sclerosis (MS) market just in the past year. Several more are nearing launch, including BMS\u2019s Zeposia and Novartis\u2019s ofatumumab, sustaining a rapid pace of change in the MS market. Developers of both current and emerging DMTs must continually reassess their products\u2019 level of differentiation and likely future role in this continually evolving and highly competitive space. This report will explore neurologists\u2019 perceptions of established and newly launched DMTs, their prescribing habits in today\u2019s market, and anticipated changes in brand usage as more DMTs expand\u2014and further complicate\u2014prescribers\u2019 choice.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>How are different MS subpopulations (i.e., clinically isolated syndrome, relapsing-remitting, secondary-progressive, and primary-progressive) treated today?<\/li>\n<li>How do product shares differ across lines of therapy? Are high-efficacy therapies (e.g., Ocrevus) factoring more into early-line treatment decisions?<\/li>\n<li>How has neurologists\u2019 prescribing changed in the past year, and why? What further changes do they expect within the next year?<\/li>\n<li>What are neurologists\u2019 opinions on the newest entrants in the MS market, and how are they incorporating these DMTs in the treatment paradigm?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p><em>Current Treatment: Physician Insights<\/em> provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n<p><strong>Markets Covered:\u00a0<\/strong>United States<\/p>\n<p><strong>Primary research:\u00a0<\/strong>Survey of 94 U.S. neurologists<\/p>\n<p><strong>Key drugs covered:\u00a0<\/strong>Aubagio, glatiramer acetate, Gilenya, interferons, Lemtrada, Mavenclad, Mayzent, Ocrevus, ofatumumab, Tecfidera, Tysabri, Vumerity, Zeposia<\/p>\n<p><strong>Key companies:\u00a0<\/strong>Biogen, Bristol Myers\u00a0Squibb, EMD Serono, Genentech, Novartis, Roche, Sanofi Genzyme<\/p>\n<p><strong>Key insights provided:\u00a0<\/strong><\/p>\n<ul>\n<li>Factors influencing disease management and treatment decisions<\/li>\n<li>Drivers and constraints of treatment selection<\/li>\n<li>Physician-reported treatment practices and brand-level patient shares<\/li>\n<li>Rationale for changes in treatment approach<\/li>\n<li>Physician insight on persistency and compliance<\/li>\n<li>Physician-reported recent\/anticipated changes in brand usage or treatment approach<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390173","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-product-current-treatment","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390173","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390173\/revisions"}],"predecessor-version":[{"id":393298,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390173\/revisions\/393298"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390173"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}